A5064055667- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Cancer, Hypoxia, and Metabolism
- Olfactory and Sensory Function Studies
- Single-cell and spatial transcriptomics
- CNS Lymphoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Acute Lymphoblastic Leukemia research
- Neuroblastoma Research and Treatments
- Neurobiology and Insect Physiology Research
- Cancer Immunotherapy and Biomarkers
- Histone Deacetylase Inhibitors Research
- Biochemical Analysis and Sensing Techniques
- Epigenetics and DNA Methylation
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Medical Imaging Techniques and Applications
- GNSS positioning and interference
- Pancreatic and Hepatic Oncology Research
- Innovations in Medical Education
Memorial Sloan Kettering Cancer Center
2016-2025
NYU Langone Health
2024-2025
New York University
2025
Wake Forest University
2024
American Academy of Neurology
2024
Brown University
2024
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2024
Kettering University
2014-2024
The University of Texas Health Science Center at Houston
2021-2024
Johns Hopkins All Children's Hospital
2023
The recent discovery of mutations in metabolic enzymes has rekindled interest harnessing the altered metabolism cancer cells for therapy. One potential drug target is isocitrate dehydrogenase 1 (IDH1), which mutated multiple human cancers. Here, we examine role mutant IDH1 fully transformed with endogenous mutations. A selective R132H-IDH1 inhibitor (AGI-5198) identified through a high-throughput screen blocked, dose-dependent manner, ability enzyme (mIDH1) to produce R-2-hydroxyglutarate...
Abstract Purpose: The genomic landscape of gliomas has been characterized and now contributes to disease classification, yet the relationship between molecular profile progression treatment response remain poorly understood. Experimental Design: We integrated prospective clinical sequencing 1,004 primary recurrent tumors from 923 glioma patients with phenotypes. Results: Thirteen percent harbored a pathogenic germline variant, including subset associated heritable genetic syndromes variants...
Abstract Background Safe sampling of central nervous system tumor tissue for diagnostic purposes may be difficult if not impossible, especially in pediatric patients, and an unmet need exists to develop less invasive tests. Methods We report our clinical experience with minimally molecular diagnostics using a clinically validated assay sequencing cerebrospinal fluid (CSF) cell-free DNA (cfDNA). All CSF samples were collected as part care, results reported both clinicians patients/families....
To perform a retrospective analysis examining the incidence and prognosis of glioma patients with leptomeningeal disease (LMD) at Memorial Sloan Kettering Cancer Center over 15-year period correlate these findings clinicopathologic characteristics.We conducted review LMD diagnosed from 2001 to 2016. Patients were identified through keyword search their electronic medical record by ICD-9 codes.One hundred three disseminated 85 subependymal spread disease, 4.7% all glioma. These cohorts...
Malignancies involving the central nervous system present unique challenges for diagnosis and monitoring due to difficulties risks of direct biopsies low specificity and/or sensitivity other techniques assessment. In recent years, liquid biopsy cerebrospinal fluid (CSF) has emerged as a convenient alternative that combines minimal invasiveness with ability detect disease-defining or therapeutically actionable genetic alterations from circulating tumor DNA (ctDNA). Since CSF can be obtained...
For patients with central nervous system (CNS) malignancies, liquid biopsies of the cerebrospinal fluid (CSF) may offer an unparalleled source information about tumor, much less risk than traditional biopsies. Two techniques have been adapted to CSF in clinical settings: circulating tumor cells (CTCs) and DNA (ctDNA). CTCs employed mostly as a diagnostic tool for leptomeningeal metastases epithelial tumors, although they also value prognostication monitoring this disease. The ctDNA...
Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal limited survival. Tumors from 173 GBM are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All were treated within the scope an individual healing attempt. Among all vaccinated patients, including 70 prior progression (primary) and 103 after (recurrent), median overall survival first diagnosis 31.9...
The embryonic development of the olfactory nerve includes differentiation cells within placode, migration into mesenchyme from and extension axons by sensory neurons (OSNs). coalition both placode-derived migratory OSN is collectively termed "migratory mass." Here we address sequence coordination events that give rise to mass. Using neuronal developmental markers, show subpopulations emerging placode day (E)10, a time at which mass largely cellular only few isolated are seen, prior first...
Malignant glioma (MG) is a devastating neuro-oncologic disease with almost invariably poor prognosis. Prognostic awareness (PA) the of incurable and shortened life expectancy (LE). Accurate PA associated favorable psychological outcomes at end (EoL) for patients cancer; however, little known about or prognostic communication in MG. Moreover, research has yet to evaluate impact cognitive impairment on preferred forms communication.Fifty MG 32 paired caregivers were evaluated this exploratory...
The phenotypic diversity of cancer results from genetic and nongenetic factors. Most studies heterogeneity have focused on DNA alterations, as technologies for proteomic measurements in clinical specimen are currently less advanced. Here, we used a multiplexed immunofluorescence staining platform to measure the expression 27 proteins at single-cell level formalin-fixed paraffin-embedded samples treatment-naive stage II/III human breast cancer. Unsupervised clustering protein data 638,577...
Extraneural metastasis of glioma is a rare event, often occurring in patients with advanced disease. Genomic alterations associated extraneural remain incompletely understood.Ten at Memorial Sloan Kettering Cancer Center diagnosed metastases glioblastoma (9 patients) and gliosarcoma (1 patient) from 2003 to 2018 were included our analysis. Patient characteristics, clinical course, genomic evaluated.Patient age diagnosis ranged 14 73, 7 men 3 women this group. The median overall survival...
Abstract A subset of glioblastomas (GBMs) harbors potentially druggable oncogenic FGFR3 - TACC3 (F3T3) fusions. However, their associated molecular and clinical features are poorly understood. Here we analyze the frequency F3T3-fusion positivity, its genetic methylation profiles, impact on survival in 906 IDH-wildtype GBM patients. We establish an F3T3 prevalence 4.1% delineate associations with cancer signaling pathway alterations. F3T3-positive GBMs had lower tumor mutational copy-number...
As odorant receptors (ORs) are thought to be critical determinants of olfactory sensory neuron (OSN) axon targeting and organization, we examined the spatiotemporal onset mice ORs expression from differentiation OSNs in placode an aging epithelium. were first detected at embryonic day 9 (E9), OSN but before extension. By E13, 22 23 expressed. Onset individual OR was diverse; levels patterns unique for each OR. Regional distribution within zones epithelium appeared stable across development;...
We report preclinical and first-in-human-brain-cancer data using a targeted poly (ADP-ribose) polymerase 1 (PARP1) binding PET tracer, [18F]PARPi, as diagnostic tool to differentiate between brain cancers treatment-related changes.We applied glioma model in p53-deficient nestin/tv-a mice, which were injected with [18F]PARPi then sacrificed h post-injection for examination. also prospectively enrolled patients undergo dynamic acquisition on dedicated positron emission tomography/magnetic...
Abstract Background: To address financial barriers that limit access to genomic profiling and precision medicine, philanthropy supported clinical testing was offered worldwide at no cost patients with select rare cancers via the Make-an-IMPACT program. Herein, we report our findings in pediatric solid or central nervous system (CNS) tumors. Methods: Tumor DNA CSF-derived circulating tumor (CSF ctDNA) analyzed using MSK-IMPACT assay, supplemented by targeted RNA panel sequencing cases....
Mechanisms influencing the development of olfactory bulb glomeruli are poorly understood. While odor receptors (ORs) play an important role in sensory neuron (OSN) axon targeting/coalescence (Mombaerts et al., 1996; Wang 1998; Feinstein and Mombaerts, 2004), recent work showed that G protein activation alone is sufficient to induce OSN coalescence (Imai 2006; Chesler 2007), suggesting activity-dependent mechanism glomerular development. Consistent with these data, projections convergence...